ライフサイエンスコーパス: seroprotection

1 with regard to an absolute titer indicating seroprotection.

2 Bs) and proportion of participants achieving seroprotection.

3 ainst avian influenza, a single dose induced seroprotection.

4 tal antibody transfer may influence neonatal seroprotection.

5 re few data on the long-term vaccine-induced seroprotection.

6 rgan transplant recipients confers sustained seroprotection.

7 ization opportunity window and could improve seroprotection.

8 ed anti-rubella virus immunoglobulin G (IgG) seroprotection.

9 dults aged >/= 80 years), among whom 80% had seroprotection.

10 TIV), with or without adjuvant, may increase seroprotection.

11 years, half of teens and adults showed H3N2v seroprotection.

12 lations of TIV do not substantially increase seroprotection.

13 A similar trend was identified for seroprotection.

14 d in a meta-analysis to provide estimates of seroprotection 2 and 5 years after the last vaccine admi

15 Two definitions of seroprotection (40 hemagglutination units (HAU) and 160

16 ificantly lower in PHIV children for measles seroprotection (57% [95% confidence interval {CI}, 52%-6

17 primary efficacy parameter was the degree of seroprotection 6 or 7 months (26 +/- 2 weeks) after begi

18 52%-62%] vs 99% [95% CI, 96%-100%]), rubella seroprotection (65% [95% CI, 60%-70%] vs 98% [95% CI, 95

19 There was evidence of transplacental seroprotection 8 days after maternal immunization (77.9%

20 -microg regimen elicited the highest rate of seroprotection (96.2%), with a geometric mean titer of a

21 This may be due to passive seroprotection afforded by the ubiquitous presence of an

22 acking seroprotection at entry, 66% attained seroprotection after dose 1 and 75% after dose 2.

23 These corroborate with excellent seroprotection after the first dose of an earlier JENVAC

24 The extent of waning of seroprotection after yellow fever vaccination depends on

25 a "complete response" (both seroresponse and seroprotection) after first vaccination was associated w

26 g children aged <5 years in 2013, among whom seroprotection again decreased to <20%.

27 oss EU/EEA while the lack of vaccine-induced seroprotection against diphtheria is of concern and dese

28 17%) of 115 infants in the placebo group had seroprotection against five or more serotypes (p<0.0001

29 ates indicate that infection induces durable seroprotection against H1N1pdm09 but not H3N2Pe09, which

30 es were completion of the 3-dose vaccine and seroprotection against hepatitis B virus (HBV).

31 inst influenza A viruses (P < .001), greater seroprotection against influenza A/H1N1 (P = .01), and g

32 lood spots (DBSs) were collected to estimate seroprotection against measles, rubella, diphtheria, and

33 day 28 and percentages of seroconversion and seroprotection, all determined by haemagglutination inhi

34 In Nayapara, estimated seroprotection among 1- to 6-year-olds was high for meas

35 The difference in the prevalence of seroprotection among the participants who received NmCV-

36 limitation of the study, may have biased the seroprotection and campaign coverage results.

37 Knowledge of the age-specific prevalence of seroprotection and incidence of seroconversion infection

38 BV-vaccinated HCW in Ghana may lack adequate seroprotection and may be prone to HBV infection.

39 Measles revaccination induced high rates of seroprotection and memory in children receiving HAART.

40 e reduction neutralization assay and rubella seroprotection and mumps seropositivity by enzyme immuno

41 Predictors of rubella seroprotection and mumps seropositivity were similar.

42 High seroprotection and seroconversion rates against all infl

43 High seroprotection and seroconversion rates against all infl

44 S aureus colonization experienced (1) lower seroprotection and seroconversion rates and lower hemagg

45 Seroprotection and seroconversion rates are not well und

46 Seroprotection and seroconversion rates are not well und

47 was descriptive and included safety events, seroprotection and seroconversion rates, and geometric m

48 Seroprotection and seroresponse (>/=4-fold rise) occurre

49 cluded geometric mean titer, seroconversion, seroprotection, and adverse events.

50 esus macaques that are correlated with human seroprotection, and it could be particularly promising f

51 Mean antibody titer change, seroprotection (antibody titer level >=1:40) and serocon

52 Furthermore, seroprotection at 10 weeks was higher in the booster gro

53 Seroprotection at 6 months was greater for those on the

54 Of women lacking seroprotection at entry, 66% attained seroprotection aft

55 Among participants who lacked seroprotection at entry, a "complete response" (both ser

56 ears later, 85% demonstrated memory based on seroprotection before or 7 days after vaccination.

57 red age-related cross-sectional estimates of seroprotection before the pandemic (during 2009) and aft

58 logic specimen was used to determine measles seroprotection by plaque reduction neutralization assay

59 observed titer levels and on seroconversion/seroprotection categories for comparison.

60 n the 10(11) VP cohort (89%; 67-99) achieved seroprotection compared with four of 22 placebo recipien

61 ng PRN titer as the comparator resulted in a seroprotection cutoff of 153 mIU/ml, similar to the esta

62 , reflecting a mirror image of the age-based seroprotection data.

63 ded in HIV-infected patients to estimate how seroprotection decreases over time in those who initiall

64 ) against five or more serotypes; and infant seroprotection (defined as anti-pneumococcus antibody co

65 The primary end point was the rate of seroprotection, defined as antibody titers of 1:40 or gr

66 Conversely, postpandemic seroprotection followed a U-shaped distribution, with de

67 More than 92% of all participants achieved seroprotection for each of the contained antigens, while

68 X, non-inferiority was assessed relative to seroprotection for serogroup W in participants who recei

69 non-inferiority was assessed in relation to seroprotection for serogroup Y in participants who recei

70 ith baseline titers had significantly higher seroprotection for the 2009-H1N1 strain (100% vs. 73%, r

71 Cumulative HBV seroprotection (>/=10 mIU/mL) was gained within 12 month

72 Children in all groups had evidence of seroprotection (>10 mIU/mL) at 1 month after the second

73 were classified as responders if, by week 3, seroprotection guidelines were met.

74 aforementioned age groups, respectively, and seroprotection (HAI titers >/= 40) was shown in 79.6%, 8

75 Seroprotection (HAI titers >=40) was more common in grou

76 in the proportion of participants achieving seroprotection (hemagglutination-inhibition antibody tit

77 Evaluable primary outcomes were seroprotection (HI titer 40) and seroconversion (4-fold

78 Seroprotection (HI titre >/=1:40) was detected in 58 (75

79 Evaluable primary outcomes were seroprotection (HI titre >=40) and seroconversion (4-fol

80 ted persons reach higher levels of influenza seroprotection if vaccinated with the high-dose trivalen

81 nation campaign coverage was consistent with seroprotection in both camps.

82 ansplacental antibody transfer occurred, but seroprotection in infants waned rapidly.

83 Rubella and diphtheria seroprotection in MSs were significantly lower among 1-

84 mproved the cumulative prediction of measles seroprotection in PHIV.

85 pB-CpG vaccine; Heplisav-B) generated higher seroprotection in prelicensure trials than did a 3-dose

86 Seroprotection increased to 89% 8 weeks postvaccination,

87 Of those lacking seroresponse (n = 43) or seroprotection (n = 37) after the first vaccination, 46.

88 Seroprotection persisted in most women postpartum.

89 Measles seroprotection persisted through age 24 months among HIV

90 These corroborate with excellent seroprotection post the first dose of an earlier JENVAC(

91 ective anti-HBs levels comparable with human seroprotection, potentially useful for hepatitis B birth

92 Frequencies of seroprotection pre-vaccination and vaccine responsivenes

93 ed NmCV-5 at age 9 months, the difference in seroprotection prevalence for NmCV-5 relative to MenACWY

94 Baseline WT seroprotection ranged between 78.7% and 87.2%; all subje

95 4 WT strains at 28 days and 6 months; year 5 seroprotection ranged between 95.7% and 97.9%.

96 The primary outcome was seroprotection rate (anti-influenza antibody titers by h

97 The primary outcome was the seroprotection rate (SPR) at M36, defined as IgG concent

98 In children, the seroprotection rate 28 days after one dose was 100% for

99 mune responses in subjects aged 18-64 years (seroprotection rate [SPR], 97.2%; seroconversion rate [S

100 The seroprotection rate against 7 serotypes was 50% in infan

101 the 98.3% confidence interval for the day 42 seroprotection rate was >/=70%, thus fulfilling the US a

102 5 ug/mL as protective for each serotype, the seroprotection rate was 50% for 7/7 serotypes and 70% fo

103 5 ug/mL as protective for each serotype, the seroprotection rate was 50% for 7/7 serotypes and 70% fo

104 children vaccinated before age 2 years, the seroprotection rate was 52% within 5 years after primary

105 The global seroprotection rate was 93% (95% CI, 86%-98%), with indi

106 lations, seroconversion rates were >/=85.7%, seroprotection rates >/=91.1%, and geometric mean titers

107 Secondary outcomes were seroprotection rates (SPR), defined as anti-HBs >10 mIU/

108 Secondary outcomes were seroprotection rates (SPR), defined as anti-HBs 10 mIU/m

109 Seroprotection rates (SPRs), seroconversion rates (SCRs)

110 After vaccination, HAI titers and seroprotection rates (the percentage of participants wit

111 Among healthy adults and children, pooled seroprotection rates after single vaccination dose were

112 The seroprotection rates after vaccination were higher in th

113 Seroconversion and seroprotection rates against influenza were similar betw

114 Among previously unvaccinated individuals, seroprotection rates against the vaccine virus were 83%

115 Primary immunogenicity outcomes were seroprotection rates and MMR-specific antibody concentra

116 Seroprotection rates and postvaccination immunoglobulin

117 However, the seroprotection rates are disappointingly low when 160 HA

118 At 6 months after immunization, seroprotection rates at 40 HAU (95% healthy and 97% lung

119 Seroprotection rates at the provincial, district, and he

120 Seroprotection rates do not differ between healthy and t

121 Seroprotection rates for influenza B, H1N1, and H3N2 wer

122 Seroprotection rates for the 9-ug and 15-ug intradermal

123 he 2 studies, with higher seroconversion and seroprotection rates found in Mali vs Ghana.

124 el were as high as in central hospitals, but seroprotection rates in areas covered by remote health c

125 Seroprotection rates in Bolikhamxay against the differen

126 h decreased antibody responses to PCV-10 and seroprotection rates in infants.

127 ess the antipneumococcal antibody titers and seroprotection rates of allogeneic HCT recipients years

128 serious adverse events, and immunogenicity (seroprotection rates on day 28 after the first vaccine d

129 Postvaccination seroprotection rates varied from 76% for serogroup Y to

130 Seroprotection rates were also higher for those who rece

131 At 12 months, seroprotection rates were higher in revaccinated patient

132 Geometric mean titers and seroprotection rates were similar between groups.

133 Seroconversion and seroprotection rates were similar in the two groups on d

134 GMTs, seroprotection rates, and seroconversion rates were comp

135 c mean titers (GMTs) between the 2 vaccines, seroprotection rates, and seroconversion rates.

136 study vaccination was associated with higher seroprotection rates, greater antibody concentrations, a

137 The post-two-dose seroprotection rates, including participants who were bo

138 comparing changes in the seroconversion and seroprotection rates.

139 on, 46.5% and 40.5% achieved seroresponse or seroprotection, respectively, after the second vaccinati

140 suggest that a two-dose regimen can achieve seroprotection similar to that of the three-dose regimen

141 HIV-infected children demonstrated seroprotection through age 12 months, but this was not s

142 eipt of 2 doses, 61.17% of subjects retained seroprotection titers at 24 months, and immunogenicity c

143 With a single dose of JENVAC, seroprotection titers lasted at least 12 months in >80%

144 BDTIIV regimen independently increased seroprotection to A/H1N1 (PR = 2.58; P = 0.021) and A/H3

145 004), whereas DDTIIV independently increased seroprotection to A/H1N1 (PR = 2.59; P = 0.021).

146 In 212 evaluable patients (105 IM, 107 ID), seroprotection to H1N1, H3N2 and B strains was 70.5%, 63

147 men with HIV and conferred similar levels of seroprotection to their infants.

148 nts and non-inferiority of novel OPV2 day 28 seroprotection versus monovalent OPV2 in infants (non-in

149 e is effective in decreasing infections, but seroprotection wanes over time.

150 ne is effective in decreasing infection, but seroprotection wanes over time.

151 SD-SD arms, percentage of patients achieving seroprotection was 75.8% and 79.4% for H1N1, 84.9% and 8

152 The lack of seroprotection was associated with a transplant performe

153 se of serum bactericidal antibody titers and seroprotection was defined as postvaccination titers of

154 Seroprotection was defined by antibody levels >=0.35 ug/

155 Seroprotection was estimated to be sustained against H1N

156 A declining prevalence of HBV seroprotection was evident over time, especially within

157 A declining prevalence of HBV seroprotection was evident over time, especially within

158 trieved from the literature, the decrease of seroprotection was modeled with a log binomial generaliz

159 Prepandemic seroprotection was negligible except for very old adults

160 Our analyses confirmed that the duration of seroprotection was shorter in HIV-infected patients and

161 In MSs, measles seroprotection was similarly high among 1- to 6-year-old

162 After both the doses, seroconversion and seroprotection were >90% for JENVAC.

163 For SA-14-14-2, seroconversion and seroprotection were 57.69% and 77.56%, respectively, on

164 D-SD arms, percentages of patients achieving seroprotection were 75.8% and 79.4% for H1N1, 84.9% and

165 Seroprevalence and seroprotection were defined as an HI titer of >/=40, and

166 participants who seroconverted and achieved seroprotection were similar between groups.

167 Pooled odds of seroconversion and seroprotection were typically lower in HIV-positive pati

168 milar to the accepted cutoff of 10 IU/ml for seroprotection, with a sensitivity of 99% and a specific